Search Results

Gain Therapeutics, Inc. announces that Matthias Alder has departed the Company in order to pursue other opportunities.

Gain Therapeutics, Inc. today releases the following letter to stockholders from its President and Chief Executive Officer Matthias Alder.

Navidea Biopharmaceuticals, Inc., a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced it will be hosting a virtual meeting of its stockholders at 1pm ET on Monday, July 8th, 2024.

Provectus Biopharmaceuticals, Inc. announced that its 2024 annual stockholder meeting, including meeting activities and a company update, will be accessible by Zoom Webinar.

Eiger BioPharmaceuticals, Inc. today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30.

Gain Therapeutics, Inc. today announced that Matthias Alder, the Company’s current Chief Operating Officer, has been appointed as the Company’s Chief Executive Officer, effective immediately.

Biopharmaceutical Market Outlook 2024-2032:

KBI Biopharma, Inc., a JSR Life Sciences company and cGMP contract development and manufacturing organization, and Argonaut Manufacturing Services, Inc., a cGMP contract manufacturing organization serving the biopharmaceutical and diagnostics industries, announced a strategic alliance offering biopharmaceutical clients with end-to-end drug substance and drug product manufacturing solutions.

Navidea Biopharmaceuticals, Inc. announced that it filed a Form 15 with the Securities and Exchange Commission to deregister its common stock, preferred stock purchase rights and Series K preferred stock under Section 12 of the Securities Exchange Act of 1934, as amended, and to suspend its reporting obligations under Section 15 of the Exchange Act.